The manufacturer of Evorel has confirmed that the full range is now available to prescribe. However, supply issues remain with a number of other oestrogen-only and combination preparations.
According to the latest information on the MIMS drug shortages tracker, Elleste Solo (estradiol), Elleste Duet Conti (estradiol/norethisterone) and Elleste Duet (sequential estradiol/norethisterone) tablets are currently out of stock.
Resupply of FemSeven (estradiol), FemSeven Conti (estradiol/levonorgestrel) and FemSeven Sequi (sequential estradiol/levonorgestrel) patches is not anticipated until the end of 2020 or early 2021. The shortages relate to an issue with the patch adhesive, which the manufacturer says it is sourcing from an alternative supplier.
Stock of the tissue-selective oestrogen complex Duavive (oestrogen/bazedoxifene) has now been exhausted following its discontinuation in 2018.
There is low stock of all strengths of Estraderm MX (estradiol) patches until July 2020.
The MIMS drug shortages tracker is updated regularly with the latest HRT availability information. To support healthcare professionals during the coronavirus pandemic, free access to the shortages tracker is currently available on an unlimited basis.
Prescribers can find suitable alternatives to unavailable HRT preparations using the MIMS HRT comparison table.